DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

DRG
  • Login
  • Products
    • Biopharma
      • Market Assessment
      • Multichannel Engagement Insights
      • Real-World Data
      • Market Access

      • Fingertip Formulary Suite
      • Managed Market Surveyor
      • Account Management Dashboard
      • U.S. Managed Markets Insights
      • Healthbase
      • Market Access Platform
      • Global Market Access Solution
    • Medtech
      • Market Insights
      • Procedure Finder
      • PriceTrack
  • Solutions
    • Solutions
      • Market Sizing and Forecasting
      • Commercial Effectiveness
      • Global Access Solutions
      • Multichannel Engagement Strategy
      • Integrated Patient Journey
      • Understanding Covered Lives
      • Learning Solutions
      • Biotech solutions
      • Medtech Solutions
      • Payer Solutions
      • Provider Solutions
    • Consulting Services
      • Consulting Services
      • HEOR & Value Communication
  • Find A Report
    • Market Assessment
    • Multichannel Engagement
    • Market Access
    • Medtech Insights
  • Events
    • Meet Us at These Events
  • DRG Perspectives
  • About Us
    • Our Company
    • About Clarivate
    • Newsroom
    • Careers
    • Contact us

DRG and its group companies would like to inform you that we have updated our website privacy policy.

Acknowledge
Home › DRG Perspectives › CAR T-Cell Therapy: Engaging the...

CAR T-Cell Therapy:

Engaging the Right Hospitals in Europe

A Visual Guide to Locating Treatment Centers

Growing from an estimated $172 million USD in 2020 to $1.35 billion USD by 2025 in major European markets alone, the CAR T-cell therapy market will gain prominence due to its curative potential, as well as commercial potential, for life sciences companies. CAR T-cell therapies represent a game-changing weapon in the oncologist’s arsenal, offering hope to patients who may have exhausted previous treatment options.

The EU5 CAR T-cell therapy market is expected to reach nearly $1.4 billion USD in 2025

CAR T-cell therapies promise to seize a sizeable share of the European market for relapsed or refractory hematological malignancies.

The first pioneering therapies represent a paradigm shift in treatment for select patients, showing durable responses and long-term disease control unrivaled by conventional therapy.

2020

$172 million USD

2025

$1.35 billion USD

Multiple myeloma

Follicular lymphoma

Chronic lymphocytic leukemia

Diffuse large B-cell lymphoma

Mantle cell lymphoma

Acute lymphoblastic leukemia

Source: Decision Resources Group, Disease Landscape & Forecast, Epidemiology

These personalized treatments are the first to be approved through the EMA’s Priority Medicines (PRIME) program, which is designed to accelerate the approval of innovative drugs; CAR T-cell therapies have the potential to address significant patient unmet medical needs in Europe.

- Rachel Webster, Principal Director, Oncology, Decision Resources Group

Over the next 5 years, keep an eye on two indications in particular: diffuse large B-cell lymphoma, because of its market potential, and multiple myeloma, as the next indication where CAR-T cell therapy will likely be introduced.

Diffuse large B-cell lymphoma

Indication with the largest CAR T-cell therapy market opportunity in Europe

$1.4BUSD

EU5 CAR T-cell therapy
market opportunity by 2025

Multiple myeloma

Next indication where CAR T-cell therapy will likely enter as a treatment option

53%

5-year growth* of the multiple myeloma CAR T-cell therapy market in EU5

* Projected (2020-2025)

Incidence rate in Europe

Diffuse large B-cell lymphoma

Multiple myeloma

Source: Decision Resources Group, Epidemiology

"In preparation for commercialization, companies developing CAR T-cell therapies will need to identify suitable hospitals for targeting and launch.

Selected hospitals must be able to perform the expensive and intensive treatment, while also serving the ideal patient audience."

- Jason Lau, Product Manager, European Real-World Data, Decision Resources Group

CAR T-cell treatment hot spots

These are the top 5 hospitals in France, Germany, and the United Kingdom by volume of patients receiving treatment for these two indications.

For optimal viewing experience change mobile orientation to landscape.

DIFFUSE LARGE B-CELL LYMPHOMA MULTIPLE MYELOMA
DIFFUSE LARGE B-CELL LYMPHOMA MULTIPLE MYELOMA
DIFFUSE LARGE B-CELL LYMPHOMA MULTIPLE MYELOMA

Rank Hospital Name Town Region Beds Ownership
1 Centre Hospitalier Régional Universitaire Besançon - Hôpital Jean-Minjoz Besançon Bourgogne-Franche-Comté 1,315 Public
2 Centre Hospitalier Universitaire de Poitiers Poitiers Nouvelle Aquitaine 1,885 Public
3 Hôpital Universitaire Pitié Salpêtrière Paris Île-de-France 1,756 Public
4 Centre Hospitalier Lyon-Sud Pierre-Bénite Auvergne-Rhône-Alpes 1,500 Public
5 Institut de Cancérologie Gustave Roussy Villejuif Île-de-France 414 Public

Rank Hospital Name Town Region Beds Ownership
1 Centre Hospitalier Universitaire de Poitiers Poitiers Nouvelle Aquitaine 1,885 Public
2 Centre Hospitalier Universitaire Limoges - Hôpital Dupuytren Limoges Nouvelle Aquitaine 892 Public
3 Centre Hospitalier Universitaire Hôpital de Bordeaux - Groupe Hospitalier Pellegrin Bordeaux Nouvelle Aquitaine 1,521 Public
4 Centre Hospitalier Régional d'Orléans Orléans Centre 1,227 Public
5 les Hôpitaux Universitaires de Strasbourg - Hôpital de Hautepierre Strasbourg Grand-Est 945 Public

Rank Hospital Name Town Region Beds Ownership
1 Charité - Universitätsmedizin Berlin - Campus Mitte Berlin Berlin 870 Public
2 Universitätsklinikum Münster Münster Nordrhein-Westfalen 1,457 Public
3 Klininkum Chemnitz gGmbH Standort Flemmingstraße 2/4 Chemnitz Sachsen 688 Private non-profit
4 Universitätsklinikum Würzburg Würzburg Bayern 1,430 Public
5 Universitätsklinikum Freiburg Freiburg im Breisgau Baden-Württemberg 1,610 Public

Rank Hospital Name Town Region Beds Ownership
1 Universitätsklinikum Würzburg Würzburg Bayern 1,430 Public
2 Klininkum Chemnitz gGmbH Standort Flemmingstraße 2/4 Chemnitz Sachsen 688 Private non-profit
3 Charité - Universitätsmedizin Berlin - Campus Mitte Berlin Berlin 870 Public
4 Kliniken Essen-Mitte gGmbH - Evangelisches Krankenhaus Essen-Werden Essen Nordrhein-Westfalen 230 Private non-profit
5 Evangelisches Krankenhaus Hamm gGmbH Hamm Nordrhein-Westfalen 464 Private non-profit

Rank Hospital Name Town Region Beds Ownership
1 Royal Marsden Hospital Sutton South East 117 Public
2 Addenbrooke's Hospital Cambridge East of England 1,060 Public
3 Leicester Royal Infirmary Leicester East Midlands 1,000 Public
4 University College Hospital Macmillan Cancer Centre London Greater London 720 Public
5 Blackpool Victoria Hospital Blackpool North West 767 Public

Rank Hospital Name Town Region Beds Ownership
1 King's Mill Hospital Sutton-in-Ashfield East Midlands 550 Public
2 Royal Papworth Hospital NHS Foundation Trust Cambridge East of England 290 Public
3 Sobell House Headington South East 18 Private non-profit
4 Leominster Community Hospital Leominster West Midlands 10 Public
5 Eastbourne District General Hospital Eastbourne South East 490 Public

Source: Decision Resources Group, European Real World Data

Key takeaways

  • In the EU5 countries, the CAR T-cell therapy market will be worth $1.35B USD by 2025
  • Diffuse large B-cell lymphoma and multiple myeloma are two key indications to watch out for
  • Ideal hospitals must be able to perform the intensive treatment and serve the optimal patient population
Request data and insights for your market

TO LEARN MORE

DRGOncology.com | questions@teamdrg.com

Diseases and Treatments MedTech Infographics

Searching for the silver lining: COVID-19 and influenza

View Now
DRG

Decision Resources Group

DRG is the premier provider of healthcare analytics, data and insight products and services to the world’s leading pharma, biotech and medical technology companies.

Read More

Company

  • About DRG
  • Careers
  • Offices
  • Locations

Resources

  • Sitemap
  • Newsroom
  • Whitepapers
  • Events
  • Reports

Support

  • Client Portal

Social

  • Linkedin
  • Facebook
  • Twitter
  • Youtube
  • Contact Us
  • Privacy & Cookies
  • Term of Use
  • Privacy Center
  • 2020 DR/Decision Resources, LLC
  • Find a Report
  • Linkedin
  • Twitter
  • Contact Us
Thank you for your ebook download,
and live webinar registration.

Don’t forget to attend on Jan. 19!

Close